 problem for the development of drugs that work for everyone in our community, right? That's why we're so focused on improving not just enrollment, but diversity of clinical trial participants. But the burden can't be fully shouldered by the patients and their families. Dornsife says there's a lot that can be done on the research side to improve the process.